EP4709853A1 - Verfahren zur prävention von durch nukleasen induzierter genotoxizität auf dem ziel - Google Patents

Verfahren zur prävention von durch nukleasen induzierter genotoxizität auf dem ziel

Info

Publication number
EP4709853A1
EP4709853A1 EP24723913.0A EP24723913A EP4709853A1 EP 4709853 A1 EP4709853 A1 EP 4709853A1 EP 24723913 A EP24723913 A EP 24723913A EP 4709853 A1 EP4709853 A1 EP 4709853A1
Authority
EP
European Patent Office
Prior art keywords
cells
cell
loh
nuclease
editing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24723913.0A
Other languages
English (en)
French (fr)
Inventor
François MOREAU-GAUDRY
Aurélie BEDEL
Sabrina FAYET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Bordeaux
Universite de Bordeaux
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Bordeaux
Universite de Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Universitaire de Bordeaux, Universite de Bordeaux filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of EP4709853A1 publication Critical patent/EP4709853A1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24723913.0A 2023-05-12 2024-05-10 Verfahren zur prävention von durch nukleasen induzierter genotoxizität auf dem ziel Pending EP4709853A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23305760 2023-05-12
PCT/EP2024/062916 WO2024235844A1 (en) 2023-05-12 2024-05-10 Methods of preventing on-target genotoxicity induced by nucleases

Publications (1)

Publication Number Publication Date
EP4709853A1 true EP4709853A1 (de) 2026-03-18

Family

ID=86760357

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24723913.0A Pending EP4709853A1 (de) 2023-05-12 2024-05-10 Verfahren zur prävention von durch nukleasen induzierter genotoxizität auf dem ziel

Country Status (2)

Country Link
EP (1) EP4709853A1 (de)
WO (1) WO2024235844A1 (de)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006074A1 (en) 1998-04-28 2004-01-08 The Government Of The United States Of America Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
ATE314370T1 (de) 2002-01-22 2006-01-15 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one
EA019094B1 (ru) 2008-08-22 2014-01-30 Новартис Аг Пирролопиримидины и их применение
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
WO2016073990A2 (en) * 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
US20210371855A1 (en) * 2018-06-15 2021-12-02 Ideaya Biosciences, Inc. Methods of inhibiting proliferative cells

Also Published As

Publication number Publication date
WO2024235844A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
JP6993063B2 (ja) ゲノムエンジニアリング
Cullot et al. CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations
US10557151B2 (en) Somatic human cell line mutations
JP2026012785A (ja) 細胞ゲノムにおける、相同組換え修復（ｈｄｒ）の効率を上昇させるための方法
Dan et al. Genetic studies on mammalian DNA methyltransferases
Yue et al. Xist RNA repeat E is essential for ASH2L recruitment to the inactive X and regulates histone modifications and escape gene expression
Acosta et al. Use of two gRNAs for CRISPR/Cas9 improves bi‐allelic homologous recombination efficiency in mouse embryonic stem cells
US20190330698A1 (en) Diabetes polygenic risk score
JP2022512773A (ja) 加齢関連クローン性造血およびそれに関係する疾患の予防
EP3645721A1 (de) Verfahren zur behandlung von krankheiten mit genbearbeitungssystemen
EP3720507A1 (de) Behandlung von parkinson-patienten mit mutationen im lrrk2-gen
JP7210028B2 (ja) 遺伝子変異導入方法
Karagyaur et al. Practical recommendations for improving efficiency and accuracy of the CRISPR/Cas9 genome editing system
Regan et al. Megabase-scale loss of heterozygosity provoked by CRISPR-Cas9 DNA double-strand breaks
WO2019018553A1 (en) METHODS OF PRODUCING HUMAN CANCER CELL MODELS AND METHODS OF USE
Ray et al. Genome editing with CRISPR-Cas9: A budding biological contrivance for colorectal carcinoma research and its perspective in molecular medicine
WO2019194751A1 (en) Use of an essentially pure mesenchymal stem cell population of the amniotic membrane of umbilical cord for generating a mammalian stem cell carrying a transgene
Sargent et al. Nuclease-mediated double-strand break (DSB) enhancement of small fragment homologous recombination (SFHR) gene modification in human-induced pluripotent stem cells (hiPSCs)
US20190341125A1 (en) Inflammatory bowel disease polygenic risk score
JP2022553855A (ja) 長さが２１～３０ヌクレオチドのガイド配列を使用したヘテロ接合ｅｌａｎｅ遺伝子の対立遺伝子のさまざまなノックアウト
Boehden et al. Recombination at chromosomal sequences involved in leukaemogenic rearrangements is differentially regulated by p53
WO2024235844A1 (en) Methods of preventing on-target genotoxicity induced by nucleases
Dyer The pathogenetic role of oncogenes deregulated by chromosomal translocation in B-cell malignancies
Miglierina et al. DIS3 licenses B cells for plasma cell differentiation in humans
US20250102493A1 (en) Compositions and methods for treatment of aneuploid cancers

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR